HOME >> MEDICINE >> NEWS
Should heart attack care be more like trauma care? Study suggests regional system could be feasible

In a heart attack, every minute counts. But should patients spend a few more of those minutes getting to a hospital that can provide the most advanced treatment, rather than just the closest hospital?

That question is at the heart of a current debate among heart specialists: whether to make heart attack care more like trauma care, with ambulance crews taking certain patients to specialized hospitals that can perform emergency heart procedures, rather than stopping at the closest hospital.

A new study looks at a crucial issue in that debate: how close Americans live to hospitals that can perform angioplasty, which is considered the best treatment for the form of heart attack called STEMI, if it's done quickly. Only a fraction of American hospitals perform angioplasties, which re-open blocked blood vessels in the heart and can be done electively to prevent a heart attack or urgently to treat one.

The new research shows that nearly 80 percent of Americans live within an hour's ambulance trip of an angioplasty-performing hospital. The University of Michigan and Yale University research team made the finding by combining and analyzing census data, hospital locations, driving distances and estimated driving times,

The researchers also found that the closest hospital to about 58 percent of Americans doesn't do angioplasty. But the extra drive time to an angioplasty hospital would be less than 30 minutes for most of them, though many patients in rural areas would have farther to go.

The research will be published March 8 in the journal Circulation, and will also be presented March 13 at the annual meeting of the American College of Cardiology.

"There are many more issues involved in regionalizing heart attack care, with proximity to specialized hospitals being necessary, but not sufficient, for making such a system feasible," says lead author Brahmajee Nallamothu, M.D., MPH. an assistant professor of internal medicine at
'"/>

Contact: Kara Gavin
kegavin@umich.edu
734-764-2220
University of Michigan Health System
6-Mar-2006


Page: 1 2 3 4

Related medicine news :

1. Should adult male circumcision be recommended for HIV prevention in the US?
2. Shoulder tapping -- Young males are most willing to purchase alcohol for underage youth
3. Should NICE evaluate complementary medicine?
4. Should Muslims have faith-based health services?
5. Should smokers be refused surgery?
6. Should patients undergoing surgery get ASA?
7. Should patients have to opt out of electronic records?
8. Assisted dying: Should it be legal?
9. Should older men be screened for prostate cancer?
10. Should we screen people for depression?
11. Should we ban consumer drug ads? - Press release from PLoS Medicine

Post Your Comments:
(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) -- ... some of the changes brought about by the disorder ... New research has found that people with diabetes who ... risk of having a severe low blood sugar (hypoglycemia) ... people with diabetes who aren,t depressed. "Depression ...
(Date:5/21/2013)... long been known for their health benefits, and ... like anti-cancer drugs are delivered to specific tumor ... how to create nanoparticles using natural lipids derived ... them as drug delivery vehicles. UofL scientists Huang-Ge ... team today (May 21, 2013), published their findings ...
(Date:5/21/2013)... Schaumburg, IL (PRWEB) May 21, 2013 ... administration for large, medium, and small organizations, will be ... featuring an experts team from Findley Davies. The presentation ... is up-to-date and in compliance with new Health Care ... ideas to engage employees. , “Benefit Express regularly ...
(Date:5/21/2013)... May 21, 2013 Dr. Francine Kaufman , ... she used with her patients in the 1980s: It weighed several ... For the most part, it could only be used in the ... years since then, and the advantages are greater as well. The ... outside of the body, often on a belt or a pocket. ...
(Date:5/21/2013)... 21, 2013 A plastic surgery ... for plastic surgery SEO services following an Internet ... to name the “Best Plastic Surgery SEO Services”. ... outcome was predictable. Well-known in the plastic surgery ... patients than any other selection based on superior ...
Breaking Medicine News(10 mins):Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 3Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2Health News:Benefit Express to Host Workplace Wellness Webinar 2Health News:Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives 2Health News:Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives 3Health News:Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives 4Health News:JD Media Surge's CosmeticSurgeonsOnline.com Voted #1 Source for Plastic Surgery SEO 2
(Date:5/21/2013)... WESTBURY, N.Y. , May 21, 2013  Vasomedical, Inc. ... specializing in the design, manufacture and sale of medical devices ... today that Dr. Jun Ma , President ... Annual Marcum LLP MicroCap Conference on Thursday, May 30, 2013 ... Grand Hyatt Hotel. The Company,s presentation is ...
(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Technologies for Optical Coherence Tomography (OCT) ... STUDY OBJECTIVES   ... study is to offer synopsis of the ...
(Date:5/21/2013)... Fla. , May 21, 2013  Janssen ... safety results from the global Phase 3 PROMISE ... inhibitor simeprevir (TMC435) led to sustained virologic response ... in 79 percent of treatment-experienced genotype 1 chronic ... including all stages of liver fibrosis, when administered ...
Breaking Medicine Technology:Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
Cached News: